C
CNS Pharmaceuticals, Inc. (CNSP)
NCM – Real Time Price. Currency in USD
3.98
-0.17 (-4.14%)
At close: Jun 26, 2026, 4:00 PM EDT
3.98
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.98
-0.17 (-4.14%)
At close: Jun 26, 2026, 4:00 PM EDT
3.98
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. E. Lynne Kelley F.A.C.S., M.D. | Chief Medical Officer |
| Mr. Christopher S. Downs CPA, CTP, FP&A | Senior Vice President of Finance |
| Mr. Dylan Wenke M.B.A. | Chief Business Officer |
| Mr. Eric Faulkner M.B.A., M.Sc. | Chief Technology Officer |
| Mr. Rami Levin M.B.A. | President, CEO & Director |
| Mr. Steve O'Loughlin M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-19 | S-3 | cns_s3.htm |
| 2026-05-19 | D | |
| 2026-05-14 | 10-Q | cns_i10q-033126.htm |
| 2026-05-04 | 8-K | cns_8k.htm |
| 2026-04-30 | 10-K/A | cns_i10ka1-123125.htm |
| 2026-03-31 | 10-K | cns_i10k-123125.htm |
| 2026-03-11 | 8-K | cns_8k.htm |
| 2026-03-02 | 8-K | cns_8k.htm |
| 2026-02-27 | S-8 | cns_s8.htm |
| 2026-02-17 | 8-K | cns_8k.htm |